Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Trial ID or NCT#

NCT04077372

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.

Official Title

A Randomized, Controlled Trial Examining the Use of The "Serious Illness Conversation Guide" (SICG) in Patients With Advanced Gastro-Intestinal Cancers

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX and FOLFIRI. - Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF V600E mutation may be enrolled regardless of prior chemotherapy. - Exception: Patients whose tumors are MSI-H must have experience progression through immunotherapy in addition to the therapies mentioned above. - Patients with metastatic pancreatic adenocarcinoma. - Patients with metastatic gastric or esophageal cancer whose tumor has progressed through first-line chemotherapy of any type. - Patients with metastatic cholangiocarcinoma whose tumor has progressed through first-line chemotherapy of any type. - Patients with metastatic hepatocellular carcinoma whose tumor has progressed through PD1 blockade. - Patients with metastatic high-grade neuroendocrine tumor. - A patient with a metastatic GIST that has progressed through first-line tyrosine kinase inhibitor. - Expected life expectancy of at least one month
Exclusion Criteria:
  1. - Any patient not meeting the above criteria - Non-English speaking patients

Investigator(s)

Tyler Johnson
Tyler Johnson
Gastrointestinal specialist, Medical oncologist
Clinical Assistant Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

Daniel Holguin
6507363379